Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Philippe Bonin"'
Autor:
Sylvaine Conord
Publikováno v:
Tessituras: Revista de Antropologia e Arqueologia, Vol 2, Iss 2 (2014)
Clique no link abaixo para assistir a palestra http://vimeo.com/115256421 Além de revisitar o tema do colóquio internacional Etnografias Plurais IV: Restituição e Difusão de Dados de Pesquisa, organizado pela Société d’Ethnologie Français
Externí odkaz:
https://doaj.org/article/9fbe8c6beea1474cb3a92ecdd2651b57
Autor:
Elise Paven, Clarisse Eveno, Philippe Bonin, Mohamed Bouattour, Sandrine Faivre, Eric Raymond, Matthieu Martinet, Annemilaï Tijeras-Raballand, Marc Pocard, Armand de Gramont, C. Hobeika
Publikováno v:
Molecular Cancer Therapeutics. 17:B145-B145
Introduction: Galunisertib, a selective ATP-mimetic TGF-β receptor (TGFβR)-I inhibitor, displays a very safe toxicity profile in clinical trials, making it suitable for combinations. Galunisertib showed activity as second-line treatment in advanced
Autor:
C. Hobeika, Clarisse Eveno, Sandrine Faivre, Eric Raymond, Mohamed Bouattour, Annemilaï Tijeras-Raballand, Matthieu Martinet, Philippe Bonin, Marc Pocard, Armand de Gramont, Elise Paven
Publikováno v:
Molecular Cancer Therapeutics. 17:B144-B144
Introduction: Notch pathway has been involved in cell fate determination, cell differentiation, proliferation, and death. Notch promotes cell survival, angiogenesis, and treatment resistance in numerous cancers, making it a promising target for cance
Autor:
Pierre-Yves Le Pennec, Philippe Rouger, Carine Auxerre, Geneviève Juszczak, Thierry Peyrard, Bach-Nga Pham, Sandrine Godin, Philippe Bonin
Publikováno v:
Transfusion. 49:1329-1334
BACKGROUND: In the Rh blood group system, published observations showed that the c antigen has the fewest variant forms of the principal antigens in this system. The partial nature of the c antigen was only reported in c+ Rh:−26 persons and to be a
Autor:
Philippe Chadebech, Anoosha Habibi, Ruben Nzouakou, Dora Bachir, Natacha Meunier-Costes, Philippe Bonin, Martine Rodet, Btissam Chami, Frederic Galacteros, Philippe Bierling, France Noizat-Pirenne
Publikováno v:
Transfusion. 49:1785-1792
BACKGROUND: Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication in sickle cell disease (SCD) characterized by recurrence of disease complications, recipient red blood cell (RBC) destruction, and frequently no detectable a
Autor:
Frédéric Galactéros, Philippe Bonin, Martine Rodet, Philippe Bierling, K. Lee, Dora Bachir, Btissam Chami, Philippe Chadebech, F. Noizat-Pirenne, Anoosha Habibi, N. Meunier
Publikováno v:
Transfusion Clinique et Biologique
Transfusion Clinique et Biologique, Elsevier, 2008, 15 (6), pp.377-382. ⟨10.1016/j.tracli.2008.10.002⟩
Transfusion Clinique et Biologique, Elsevier, 2008, 15 (6), pp.377-382. ⟨10.1016/j.tracli.2008.10.002⟩
Background: Prevention of hemolytic transfusion reactions depends upon our capacity to prevent allo-immunization and conflicts between antigens of transfused red blood cells and antibodies produced by the recipient. In this study, we show that to sec
Autor:
France Noizat-Pirenne, Martine Verdier, Annette Lejealle, Anne Mercadier, Philippe Bonin, Françoise Peltier-Pujol, Anne Fialaire-Legendre, Christophe Tournamille, Philippe Bierling, Hélène Ansart-Pirenne
Publikováno v:
Transfusion. 47:1616-1620
BACKGROUND: Weak D Types 1, 2, and 3 recipients cannot be immunized when exposed to D antigen. Molecular biology is very efficient to type weak D variants but rarely implemented in daily practice. The serologic typing practice of weak D in a Caucasia
Autor:
Blais-Sénéchal, Gabrielle
Publikováno v:
Circuit: Musiques Contemporaines. 2022, Vol. 32 Issue 3, p91-96. 6p.
Publikováno v:
Journal of Endodontics. 24:359-363
Nd:YAP laser is a dental laser with a 1340 nm wavelength. The laser beam is carried by a 200 to 300 microns fiberoptic and is suitable for endodontic therapy. We used the Nd:YAP laser in an in vitro experiment to study its effectiveness in endodontic
Autor:
Dominique Desvaux-Belghiti, H Terzidis, Claude Philippon, Gilbert Lagrue, M Petit-Phar, Bertrand Weil, Philippe Bierling, Liliane Intrator, Serge Adnot, Philippe Remy, Guy Rostoker, Philippe Lang, Philippe Bonin, Deforges L, Chantal Andre, Yannick Pilatte
Publikováno v:
Nephron. 69:327-334
Recently, our group has shown that a 3-month course of intravenous immunoglobulin (2 g/kg/monthly) followed by 6 months of intramuscular immunoglobulins (IMIG, 16.5%, 0.35 ml/kg every 15 days) was abl